title: Hypertrophic cardiomyopathy. Clinical spectrum and treatment.
abstract: HCM is a heterogeneous disease genotypically, phenotypically, pathophysiologically, clinically, and therapeutically. In decisions on the management of these patients, it is important to recognize this heterogeneity and to direct therapy at the predominant abnormalities.
authors.affiliation: Division of Cardiology, Toronto Hospital, Ontario, Canada.
authors.forename: E D
authors.initials: ED
authors.lastname: Wigle
authors.forename: H
authors.initials: H
authors.lastname: Rakowski
authors.forename: B P
authors.initials: BP
authors.lastname: Kimball
authors.forename: W G
authors.initials: WG
authors.lastname: Williams
mesh_terms: D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001281:Atrial Fibrillation / Q000209:etiology; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002312:Cardiomyopathy, Hypertrophic / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000502:physiology; D017202:Myocardial Ischemia / Q000503:physiopathology; D010138:Pacemaker, Artificial; D017180:Tachycardia, Ventricular / Q000209:etiology; D014693:Ventricular Fibrillation / Q000209:etiology; D016277:Ventricular Function, Left / Q000502:physiology
chemical_list: D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers